Your browser doesn't support javascript.
loading
Epigenomic mapping reveals distinct B cell acute lymphoblastic leukemia chromatin architectures and regulators.
Barnett, Kelly R; Mobley, Robert J; Diedrich, Jonathan D; Bergeron, Brennan P; Bhattarai, Kashi Raj; Monovich, Alexander C; Narina, Shilpa; Yang, Wenjian; Crews, Kristine R; Manring, Christopher S; Jabbour, Elias; Paietta, Elisabeth; Litzow, Mark R; Kornblau, Steven M; Stock, Wendy; Inaba, Hiroto; Jeha, Sima; Pui, Ching-Hon; Mullighan, Charles G; Relling, Mary V; Pruett-Miller, Shondra M; Ryan, Russell J H; Yang, Jun J; Evans, William E; Savic, Daniel.
Afiliación
  • Barnett KR; Hematological Malignancies Program, St. Jude Children's Research Hospital, Memphis, TN 38105, USA; Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
  • Mobley RJ; Hematological Malignancies Program, St. Jude Children's Research Hospital, Memphis, TN 38105, USA; Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
  • Diedrich JD; Hematological Malignancies Program, St. Jude Children's Research Hospital, Memphis, TN 38105, USA; Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
  • Bergeron BP; Hematological Malignancies Program, St. Jude Children's Research Hospital, Memphis, TN 38105, USA; Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN 38105, USA; Graduate School of Biomedical Sciences, St. Jude Children's Research Hospital, Memphis
  • Bhattarai KR; Hematological Malignancies Program, St. Jude Children's Research Hospital, Memphis, TN 38105, USA; Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
  • Monovich AC; Department of Pathology, University of Michigan-Ann Arbor, Rogel Cancer Center, Ann Arbor, MI 48109, USA.
  • Narina S; Center for Advanced Genome Engineering, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
  • Yang W; Hematological Malignancies Program, St. Jude Children's Research Hospital, Memphis, TN 38105, USA; Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
  • Crews KR; Hematological Malignancies Program, St. Jude Children's Research Hospital, Memphis, TN 38105, USA; Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
  • Manring CS; Alliance Hematologic Malignancy Biorepository, Clara D. Bloomfield Center for Leukemia Outcomes Research, Columbus, OH 43210, USA.
  • Jabbour E; Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
  • Paietta E; Department of Oncology, Montefiore Medical Center, Bronx, NY 10467, USA.
  • Litzow MR; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
  • Kornblau SM; Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
  • Stock W; University of Chicago Comprehensive Cancer Center, Chicago, IL 60637, USA.
  • Inaba H; Hematological Malignancies Program, St. Jude Children's Research Hospital, Memphis, TN 38105, USA; Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
  • Jeha S; Hematological Malignancies Program, St. Jude Children's Research Hospital, Memphis, TN 38105, USA; Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
  • Pui CH; Hematological Malignancies Program, St. Jude Children's Research Hospital, Memphis, TN 38105, USA; Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
  • Mullighan CG; Hematological Malignancies Program, St. Jude Children's Research Hospital, Memphis, TN 38105, USA; Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
  • Relling MV; Hematological Malignancies Program, St. Jude Children's Research Hospital, Memphis, TN 38105, USA; Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
  • Pruett-Miller SM; Center for Advanced Genome Engineering, St. Jude Children's Research Hospital, Memphis, TN 38105, USA; Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
  • Ryan RJH; Department of Pathology, University of Michigan-Ann Arbor, Rogel Cancer Center, Ann Arbor, MI 48109, USA.
  • Yang JJ; Hematological Malignancies Program, St. Jude Children's Research Hospital, Memphis, TN 38105, USA; Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN 38105, USA; Graduate School of Biomedical Sciences, St. Jude Children's Research Hospital, Memphis
  • Evans WE; Hematological Malignancies Program, St. Jude Children's Research Hospital, Memphis, TN 38105, USA; Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
  • Savic D; Hematological Malignancies Program, St. Jude Children's Research Hospital, Memphis, TN 38105, USA; Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN 38105, USA; Graduate School of Biomedical Sciences, St. Jude Children's Research Hospital, Memphis
Cell Genom ; 3(12): 100442, 2023 Dec 13.
Article en En | MEDLINE | ID: mdl-38116118
ABSTRACT
B cell lineage acute lymphoblastic leukemia (B-ALL) is composed of diverse molecular subtypes, and while transcriptional and DNA methylation profiling has been extensively examined, the chromatin landscape is not well characterized for many subtypes. We therefore mapped chromatin accessibility using ATAC-seq in primary B-ALL cells from 156 patients spanning ten molecular subtypes and present this dataset as a resource. Differential chromatin accessibility and transcription factor (TF) footprint profiling were employed and identified B-ALL cell of origin, TF-target gene interactions enriched in B-ALL, and key TFs associated with accessible chromatin sites preferentially active in B-ALL. We further identified over 20% of accessible chromatin sites exhibiting strong subtype enrichment and candidate TFs that maintain subtype-specific chromatin architectures. Over 9,000 genetic variants were uncovered, contributing to variability in chromatin accessibility among patient samples. Our data suggest that distinct chromatin architectures are driven by diverse TFs and inherited genetic variants that promote unique gene-regulatory networks.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Cell Genom Año: 2023 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Cell Genom Año: 2023 Tipo del documento: Article